Volume 3, Issue 2 (9-2017)                   Iran J Neurosurg 2017, 3(2): 51-57 | Back to browse issues page


XML Print


1- MSc, Animal Physiology Department, Basic Sciences Faculty, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
2- MD, Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran
3- MD, Brain and Spinal Cord Injury Research Center (BASIR), Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran
4- MD, Department of Anesthesiology, Sina hospital, Tehran University of Medical Sciences, Tehran, Iran
5- PhD, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran , razeghi@sina.tums.ac.i
Abstract:   (8662 Views)
Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury.

Methods and Materials/Patients: Thirty patients with moderate to severe traumatic brain injury admitted to the intensive care unit were enrolled. The patients were randomly allocated to treatment with either a daily oral dose of 400 mg epigallocatechin-3-gallate or placebo (distilled water) for seven days. The main outcome measures were duration of mechanical ventilation and ICU stay, Glasgow Coma Scale, and S100B protein level.

Results: The results revealed a significant improvement in consciousness level after seven days in the epigallocatechin-3-gallate group (2.93±3.9 unit improvement in GCS versus 0.14±3.05 reduction in GCS, p-value:0.033). There was also a significantly shorter duration of mechanical ventilation in the epigallocatechin-3-gallate compared to the control group (5.1 days versus 9.8 days, p-value:0.02). Reduction of the serum S100B level was slightly higher in the epigallocatechin-3-gallate group (23.96 versus 18.6 pg/ml) but the difference was not statistically significant.

Conclusion: Epigallocatechin-3-gallate supplementation had beneficial effects on consciousness level of the patients with moderate to severe traumatic brain injury in the acute phase.

 
Full Text [PDF 464 kb]   (2388 Downloads) |   |   Full Text (HTML)  (3903 Views)  
Type of Study: Clinical Trial | Subject: Neurotrauma

References
1. Bruns JR, Hauser WA. The epidemiology of traumatic brain injury. a review. Epilepsia. 2003; 44: 2-10. [DOI:10.1046/j.1528-1157.44.s10.3.x] [PMID]
2. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007;99: 4-9. [DOI:10.1093/bja/aem131] [PMID]
3. Leon-Carion j, Barroso Y marrtin JM. Epidemiology of traumatic brain injury and subarachnoid hemorrhage. J Pituitary. 2005; 8: 197-202. [DOI:10.1007/s11102-006-6041-5] [PMID]
4. Faria A, Meireles M, Fernandes I, Santos-Buelga C, Gonzalez-Manzano S, Due-as M, de Freitas V, Mateus N, Calhau C. Flavonoid metabolites transport across a human BBB model. Food Chem. 2014 Apr 15;149:190-6. [DOI:10.1016/j.foodchem.2013.10.095] [PMID]
5. Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. I. Blood pressure and oxygenation. J Neurotrauma. 2007;24 Suppl 1:S7-13. [PMID]
6. Alexander M. Mild traumatic brain injury. pathophysiology, natural history, and clinical management. Neurology. 1995; 45(7): 50 - 60. [DOI:10.1212/WNL.45.7.1253]
7. Kuptniratsaikul V, Kovindha A, Suethanapornkal S.Complications during the rehabilitation period in thai patients with stroke: A Multi center prospective study. AMJ Phys Med Rehabil. 2009; 88(2): 92-99. [DOI:10.1097/PHM.0b013e3181909d5f] [PMID]
8. Castellano C. Psychopharmacology of memory modulation: evidence hormones.J Behave Brain Res. 1996; 34(8): 1-21. [DOI:10.1016/0166-4328(96)00200-8]
9. Rosenfeldt F, Wilson M. population, pathophysiology and therapy. J Exp Gerontol. 2013;48:45-54. [DOI:10.1016/j.exger.2012.03.010] [PMID]
10. Chen SD, Yang DI, Lin TK, Shaw FZ, Liou CW, Chuang YC. Roles of oxidative stress, apoptosis, PGC-1 and mitochondrial biogenesis in cerebral ischemia. J Mol Sci . 2011; 12: 7199–215. [DOI:10.3390/ijms12107199] [PMID]
11. Higdon J. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions.J Food Sci Nutr. 2003;43: 89-143. [DOI:10.1080/10408690390826464]
12. Anna K. Flavonoids and the CNS, Molecules. 2011; 16: 1471-1485. [DOI:10.3390/molecules16021471] [PMID]
13. Croft KD. (1998). The chemistry and biological effects of flavonoids and phenolic acids. Ann NY Acad Sci. 854:435. [DOI:10.1111/j.1749-6632.1998.tb09922.x] [PMID]
14. Middleton E J. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol. 2000; 439:175-82. [DOI:10.1007/978-1-4615-5335-9_13]
15. Hanasaki Y, Ogawa S, Fukui S. The correlation between active oxygens scavenging, and antioxidative effects of flavonoids. Free Radic Biol Med. 1994;16:845-50 [DOI:10.1016/0891-5849(94)90202-X]
16. BloomfieldSM, Mcknney J, Smith L, Brisman. Reliability of S100B in predicting severity of central nervous system injury. Neurocritic Care. 2007; 6:121-138. [DOI:10.1007/s12028-007-0008-x] [PMID]
17. Woertgen C, Holzschuh M, Metz C, Brawanski A. Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma. 1999; 47: 1126-1130. [DOI:10.1097/00005373-199912000-00026] [PMID]
18. Itoh T, Tabuchi M, Mizuguchi N, Imano M, Tsubaki M, Nishida S. Neuroprotective effect of epigallocatechin-3-gallate in rats when administered pre- or post-traumatic brain injury. J Neural Transm. 2013 ;120(5):767–783. [DOI:10.1007/s00702-012-0918-4] [PMID]
19. Hua W, Hui-Chin Tu, and Jeng-Yung.Epigallocatechin gallate attenuates NADPH-d/nNOS expression in motor neurons of rats following peripheral nerve injury. J BMC Neuroscience. 2011; 12:52. [DOI:10.1186/1471-2202-12-52] [PMID]
20. Zink BJ, SymzdYnjer-Chodobska J, Chodobski A. Emerging concepts in the pathophysiology of traumatic brain injury. Psychiat Clin North Am. 2010; 33: 741-756. [DOI:10.1016/j.psc.2010.08.005] [PMID]
21. Karpiak SE, Serokosz M, Rapport MM. Effects of antisera to S100 protein and to synaptic membrane fraction on maze performance and EEG. Brain Res. 1976; 313- 21. [DOI:10.1016/0006-8993(76)90885-4]
22. Kleindienst A, McGinn M, Harvey H, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma. 2005;22(2):645– 655. [DOI:10.1089/neu.2005.22.645] [PMID]
23. Hanasaki Y, Ogawa S, Fukui S. The correlation between active oxygens scavenging, and antioxidative effects of flavonoids. Free Radic Biol Med . 1994; 16:845-5. [DOI:10.1016/0891-5849(94)90202-X]
24. Mirrahimi B, Mortazavi A, Nouri M, Ketabchi E, Amirjamshidi A, Ashouri A, Khajavi M, Mojtahedzadeh M. Effect of magnesium on functional outcome and paraclinical parameters of patients undergoing supratentorial craniotomy for brain tumors: a randomized controlled trial. Acta Neurochir. 2015; 157(6):985. [DOI:10.1007/s00701-015-2376-x] [PMID]
25. Etezadi F, Aklamli M, Najafi A, Khajavi M, Shariat Moharari R, Mirrahimi B, Mortazavi SA, Mojtahedzadeh M. Evaluation of the anti-inflammatory effects of peri-operative infusion of magnesium sulfate on the microsurgical procedures for intracranial tumors. Anesth Pain Med. 2014;30;4(5):e22379.
26. Chen SD, Yang DI, Lin TK, Shaw FZ, Liou CW, Chuang YC. Roles of oxidative stress, apoptosis, PGC-1 and mitochondrial biogenesis in cerebral ischemia. J Mol Sci. 2011; 12: 7199–215. [DOI:10.3390/ijms12107199] [PMID] [PMCID]
27. Chan PH.Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001; 21(1):2-14. [DOI:10.1097/00004647-200101000-00002] [PMID]
28. Yun HJ, Yoo WH, Han MK, Lee YR, KiLee SI. Epigallocatechin-3-gallate suppresses T NF a lpha -induced p roduction of M MP-1 a nd -3 i n r heumatoid arthritis synovial fibroblasts. Rheumatol Int. 2008;29(1): 23–9. [DOI:10.1007/s00296-008-0597-5] [PMID]
29. Renno WM, Saleh F, Klepacek I, Al-Khaledi G, Ismael H, Asfar S. Green tea pain modulating effect in sciatic nerve chronic constriction injury rat model. Nutr Neurosci. 2006; 9(1-2): 41-7. [DOI:10.1080/10284150600576705] [PMID]
30. Herges K. Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation. PLoS ONE. 2011; 6(10): e25456. [DOI:10.1371/journal.pone.0025456]

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.